Peptide Research
Explore the latest scientific research, clinical studies, and academic papers on peptides curated by our team.
Research Spotlight
Incretin Peptides: From Diabetes Therapy to a New Era of Weight Management
Therapeutic area: Metabolic
Status: FDA-approved
The GLP-1 receptor agonist class is the most clinically validated area of modern peptide medicine. Semaglutide was evaluated in the STEP program for weight management and the SUSTAIN program for type 2 diabetes; the landmark STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) reported substantial, sustained weight loss versus placebo in adults with obesity. Tirzepatide, a dual GIP/GLP-1 receptor agonist, followed with the SURPASS trials in diabetes and the SURMOUNT trials in obesity, generally reporting even larger reductions in body weight and HbA1c. Both molecules are FDA-approved and supported by large, randomized, placebo-controlled evidence — a stark contrast to the mostly preclinical status of many other peptides.
Browse the literature on PubMed →
The summaries below are curated, plain-language overviews of well-known peptide research areas, grouped by therapeutic focus. Each notes the approximate status of the evidence — from early preclinical work to FDA-approved therapy. These are educational research summaries, not citations of specific papers and not medical advice; follow the PubMed links to read the primary literature directly.
Tissue Repair & Regeneration
Tissue Repair
BPC-157 and Tendon, Muscle & Gut Healing
BPC-157, a synthetic peptide derived from a protein found in gastric juice, has been studied extensively by the Sikiric group in Croatia. Animal models report accelerated healing of tendon, ligament, muscle, and gastrointestinal tissue, with proposed mechanisms involving angiogenesis and growth-factor signaling. Evidence is overwhelmingly preclinical; robust human clinical trials are lacking.
Tissue Repair
Thymosin Beta-4 / TB-500 in Wound & Cardiac Repair
Thymosin Beta-4 is a naturally occurring actin-binding peptide studied for wound healing, corneal repair, and cardiac regeneration. Work by Goldstein and colleagues characterized its role in cell migration, while Bock-Marquette and collaborators reported cardioprotective and repair effects after injury in animal models. TB-500 is a related fragment. Mostly preclinical, with some early clinical investigation.
Skin & Longevity
GHK-Cu: Copper-Peptide Skin & Gene Modulation
The copper-binding tripeptide GHK-Cu has been investigated for decades, notably by Pickart, for wound healing, skin remodeling, and broad effects on gene expression. Studies report stimulation of collagen and modulation of hundreds of genes toward a more youthful profile. It is widely used in cosmetic formulations; deeper therapeutic claims remain largely preclinical.
Longevity
Epitalon & Telomerase / Pineal Regulation
Epitalon (epithalon) is a synthetic tetrapeptide studied by Khavinson and colleagues in Russia for effects on the pineal gland, melatonin regulation, and telomerase activity. Some studies report telomere-related and longevity outcomes in cell and animal models. The literature is concentrated within a small research network and remains preclinical; independent replication is limited.
Metabolic & Endocrine
Metabolic
Semaglutide: The STEP & SUSTAIN Programs
Semaglutide is a GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management. The STEP trials (weight management) and SUSTAIN trials (glycemic control) form its evidence base; STEP 1 in the NEJM (2021) reported roughly 15% average body-weight reduction versus placebo. Among the most rigorously evidenced peptides in clinical use.
Metabolic
Tirzepatide: Dual GIP/GLP-1 (SURPASS & SURMOUNT)
Tirzepatide activates both the GIP and GLP-1 receptors. The SURPASS program established efficacy in type 2 diabetes, and the SURMOUNT program (SURMOUNT-1, NEJM 2022) demonstrated large weight-loss results in obesity, with some doses exceeding 20% average reduction. FDA-approved for diabetes and weight management, backed by large randomized trials.
Growth Hormone
Ipamorelin & CJC-1295: GH Pulsatility
Ipamorelin (a selective ghrelin-mimetic GH secretagogue) and CJC-1295 (a GHRH analog) are studied for their ability to stimulate the body's own pulsatile growth-hormone release rather than supplying exogenous GH. Research focuses on GH and IGF-1 dynamics. Largely preclinical and early-stage; not FDA-approved for performance or anti-aging use.
Antimicrobial
LL-37 & Host-Defense Antimicrobial Peptides
LL-37 is the human cathelicidin antimicrobial peptide, a component of innate immunity studied for direct antimicrobial activity, immune modulation, and wound healing. It is a model system in the broader effort to develop antimicrobial peptides against drug-resistant pathogens. Research is active but predominantly preclinical, with translational challenges around stability and toxicity.
Research disclaimer.
These summaries are curated for educational and research-information purposes only and describe the general state of the published literature. They are not medical advice, not therapeutic claims, and not endorsements of any compound for human use. Evidence levels vary widely — most peptides discussed here are preclinical, and only the incretin therapies are FDA-approved. Always consult primary sources (linked above) and qualified professionals.